Top Markets
#1 Threshold Network Threshold Network +62.22%
#2 TENDIES TENDIES +59.58%
#3 Cash Cat Cash Cat +20.67%
#4 OSK OSK +15.99%
#5 Magma Finance Magma Finance +13.45%
#6 Ape and Pepe Ape and Pepe +12.62%
#7 Kite Kite +11.97%
#8 Falcon Finance Falcon Finance +11.18%
#9 Asteroid Shiba Asteroid Shiba +10.17%
#10 Maple Finance Maple Finance +10.08%
Coin of the day
Threshold Network Threshold Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Healios K.K. Healios K.K.

Healios K.K.

4593
Kedudukan dalam Saham #17173
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011,... Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Harga Saham
$1.89
Modal Pasaran
$254.55M
Perubahan (1 hari)
-2.03%
Perubahan (1 tahun)
-48.53%
Negara
JP
Perdagangan Healios K.K. (4593)

Kategori

Healthcare
Nisbah P/E bagi Healios K.K. (4593)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Healios K.K., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Healios K.K. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.